Effects of Breviscapine injection on coagulation function and cerebrovascular endothelial functional status in focal cerebral ischemia rats.

OBJECTIVE

In this study, we investigated the effects of Breviscapine injection on coagulation function and cerebrovascular endothelial functional status in focal cerebral ischemia (CI) rats.

METHODS

Rats were divided into four groups: Sham, Model, low-dose Breviscapine (Bre-L, 25 mg/kg), and high-dose Breviscapine (Bre-H, 50 mg/kg). Except for the Sham group, focal CI models were induced in the other groups. Neurological function was assessed, and blood and brain tissue samples were collected to measure inflammatory cytokine levels, coagulation function indicators, and cerebrovascular endothelial function indicators. HE staining was performed to observe pathological brain damage.

RESULTS

Compared with the Sham group, the Model group showed increased levels of TNF-α, IL-1β, IL-6, and ICAM-1, shortened CT, TT, and BT, decreased levels of NO, eNOS, PGI2, and t-PA, increased levels ofTXA2, PAI activity, thrombin, and coagulation factor Xa, higher Longa scores, and marked focal CI-related brain damage. Compared with the Model group, both the Bre-L and Bre-H groups exhibited prolonged CT, TT, and BT, increased levels of NO, eNOS, PGI2, and t-PA, decreased levels of TNF-α, IL-1β, IL-6, ICAM-1, TXA2, PAI activity, thrombin, and coagulation factor Xa, and lower Longa scores. Histopathological analysis indicated reduced brain tissue damage, with the high-dose group showing more pronounced improvements than the low-dose group (p < 0.05).

CONCLUSION

Breviscapine injection can ameliorate inflammation, improves neurological and coagulation function, and restores cerebrovascular endothelial function in rats with focal CI, with a dose-dependent effect.